Available Technologies

Browse Penn-owned technologies available for licensing.


Preventing and treating osteoarthritis with Fc-fused Human Osteoclast Associated Receptors (hOSCAR)


Brief Description:

Inactive OSCAR sequesters ligands reducing activation of osteoclasts which degrade bone and joints in osteoarthritis.



Osteoarthritis is a common form of arthritis that can be caused by genetic factors, obesity, joint overuse, or pre-existing joint disorders. Without a cure, osteoarthritis gradually worsens leading to wear and tear on the cartilage causing collagen to break off in the joint. Collagen can activate osteoclast associated receptors (OSCAR) leading to the resorption of bone. Currently, patients are only treated for pain. In order to actually remedy the arthritis, a therapeutic has been developed that uses fragments of OSCAR fused to an antibody which help limit the activation of osteoclast.


Osteoarthritis is characterized by a gradual worsening of cartilage destruction that affects millions of people regardless of age. The wear and tear of cartilage releases collagen that activates OSCAR causing osteoclast to degrade the bone that structure the joint. The lack of a cure leads to future joint decay while patients are only treated for pain.


Dr. Yongwon Choi developed a novel therapeutic (RCB001) by fusing a human soluble form of the extracellular domain of OSCAR to the Fc region of IgG1. The therapeutic works by using this inactive receptor to sequester the ligands for receptors on actual osteoclast. By reducing the availability free ligands, the therapeutic offers a means of preventing or treating osteoarthritis.





·         Potentially treats early stage osteoarthritis

·         Treats and reduces existing cartilage damages in experimental models

·         Beneficial effects in experimental models are seen within a few weeks



·         Treating osteoarthritis

·         Developing new osteoarthritis animal models


Stage of Development:

·         Therapeutic that effectively prevent and attenuate cartilage damage in experimental models

·         In vivo testing


Intellectual Property:

WIPO Patent Application

WO 2016/164468A3


Reference Media:

Barrow, A.D. et al. J. Clinical Invest. 121(): 3505-3516 , 2011


Desired Partnerships:




Docket # 16-7680

Patent Information:
For Information, Contact:
Neal Lemon
Associate Director, PSOM Licensing Group
University of Pennsylvania
Yongwon Choi